Therapy delivery technology
The company uses proprietary delivery technology to transform therapies.
Source: LinkedIn company description · Retrieved October 13, 2026
Starton Therapeutics is a Phase 2 clinical-stage biotechnology platform company.
The company’s initial focus is treating hematologic malignancies with STAR-LLD, a controlled low-dose formulation of lenalidomide. The company is investigating STAR-LLD in combination with T-cell engager and CAR-T cell therapies for lymphoma and multiple myeloma.
Based on the company’s public LinkedIn information, supplied through RevenueBase.
The company uses proprietary delivery technology to transform therapies.
Source: LinkedIn company description · Retrieved October 13, 2026
STAR-LLD is the company’s lead candidate, a controlled low-dose formulation of lenalidomide.
Source: LinkedIn company description · Retrieved October 13, 2026
Supported appearances on published RevenueBase lists, including available memberships beyond displayed rankings.
Positions describe ordering within each source list. See how lists are built ↗
Embeddable award for your website
Snapshot: September 21, 2026
RevenueBase prepared this profile from the company’s public LinkedIn information and RevenueBase company data. These source records were retrieved on October 13, 2026. AI helped summarize these sources, with a separate automated check against the source text completed on November 4, 2026. Directory positions use company-contact counts from separate saved list snapshots dated September 16, 2026, September 18, 2026, September 19, 2026 and September 21, 2026. How the company lists are built.
Share a correction, your relationship to the company, and supporting sources. Requests are reviewed before changes are published.
Explore more companies by name, headquarters and business focus.